Caffeic Acid Phenethyl Ester (CAPE) / Casp3 Cancer Research Results

CAPE, Caffeic Acid Phenethyl Ester (CAPE): Click to Expand ⟱

Features:

Caffeic Acid Phenethyl Ester (CAPE) — CAPE is a propolis-derived phenolic ester and bioactive honeybee-hive constituent with pleiotropic anti-inflammatory and antineoplastic signaling effects. It is best classified as a natural polyphenolic small molecule and experimental adjunct candidate rather than an approved anticancer drug. Standard abbreviations include CAPE; common chemical naming includes caffeic acid phenethyl ester and phenethyl caffeate. CAPE is most strongly associated with poplar-type propolis chemistry, but it is also available as an ingredient in some dietary-supplement products. Current oncology relevance remains preclinical to early translational, with growing interest in chemosensitization and radiosensitization but no established cancer indication.

Primary mechanisms (ranked):

NF-κB pathway inhibition with downstream suppression of pro-inflammatory and pro-survival transcription
PI3K/Akt and p70S6K network suppression with reduced proliferation and survival signaling
Wnt/β-catenin/TCF inhibition with reduced cyclin D1 and c-MYC signaling
Anti-invasive / anti-metastatic modulation via reduced MMP expression and related motility programs
Mitochondrial and metabolic stress reprogramming, including membrane depolarization and a shift toward glycolysis in some tumor models
Chemo/radiosensitization in selected models, including autophagy inhibition and context-dependent enhancement of cytotoxic therapy
Secondary redox and cytoprotective modulation, including ROS buffering or oxidative stress induction depending on model and exposure
Secondary eicosanoid/inflammatory enzyme effects, including COX-2 and lipoxygenase-related signaling suppression

Bioavailability / PK relevance: Oral translation is constrained by poor aqueous solubility, limited absorption, esterase-sensitive disposition, and substantial hydrolysis to caffeic acid in vivo. Rat PK work supports measurable exposure after oral dosing, but CAPE analogues with improved permeability outperform parent CAPE. Formulation strategies are therefore mechanistically relevant for systemic use.

In-vitro vs systemic exposure relevance: Many direct anticancer studies use roughly 10–60 μM exposure, with some effects emerging near or above this range; those concentrations may exceed or stress the upper edge of practical systemic exposure with simple oral delivery. Tumor-directed claims should therefore be weighted more heavily when supported by in vivo xenograft, radiosensitization, or formulation-enabled data rather than cell culture alone.

Clinical evidence status: Predominantly preclinical with in vitro, xenograft, and ex vivo support; small translational signals exist for radiosensitization/radioprotection concepts, but there is no established oncology trial program or approved cancer use for CAPE itself.

CAPE — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	NF-κB inflammatory transcription	NF-κB ↓; inflammatory/pro-survival gene programs ↓	Inflammatory stress ↓	P/R	Anti-inflammatory and anti-survival signaling suppression	Most canonical CAPE axis; supported by classic mechanistic work and newer radiosensitization studies. Central for cytokine, survival, and stress-response attenuation.
2	PI3K/Akt / p70S6K / c-MYC	Akt ↓; p70S6K ↓; c-MYC ↓; proliferation ↓	↔ / protective (context-dependent)	R/G	Cytostatic and pro-apoptotic pressure	Strong relevance in prostate and NSCLC models; appears therapeutically leveraged in combination settings.
3	Wnt / β-catenin / TCF	β-catenin ↓; nuclear β-catenin ↓; cyclin D1 ↓; c-MYC ↓	↔	R/G	Growth arrest and apoptosis support	Well supported in colon cancer models; helps explain antiproliferative and differentiation-related effects.
4	MMP invasion / metastasis axis	MMP-2 ↓; MMP-9 ↓; MT1-MMP ↓; invasion ↓	ECM injury/inflammation ↓ (context-dependent)	R/G	Anti-invasive and anti-metastatic effect	Useful translational axis because it links inflammatory signaling to motility and matrix remodeling.
5	Mitochondria / metabolic reprogramming	Mitochondrial membrane potential ↓; respiration shift toward glycolysis	Potential radioprotective anti-inflammatory support in tissue slices	P/R	Stress amplification and therapeutic-window modulation	Recent lung data suggest CAPE can destabilize tumor bioenergetics while dampening inflammatory injury signals in normal tissue contexts.
6	Autophagy / chemosensitization	Autophagy ↓; oxaliplatin sensitivity ↑	↔	R/G	Adjunct sensitization to therapy	Now a meaningful secondary axis; 2024 colon-cancer work supports autophagy inhibition as one mechanism of drug sensitization.
7	Radiosensitization	RadioS ↑ (adenocarcinoma-selective in some models)	Radiation-associated inflammatory injury ↓ (context-dependent)	R/G	Potential therapeutic-window expansion	Important emerging translational niche rather than a universal CAPE effect; appears histology- and context-dependent.
8	ROS / NRF2 redox modulation (secondary)	ROS ↔ / ↑ / ↓ (context-dependent); NRF2 ↔ / ↑ (secondary)	ROS injury ↓; cytoprotective antioxidant tone ↑ (context-dependent)	P/R/G	Redox buffering or oxidative stress depending on setting	CAPE is not best treated as a simple antioxidant. In tumors it may contribute to stress and death signaling, while in normal tissue it may support anti-inflammatory/radioprotective responses.
9	COX-2 / lipoxygenase inflammatory eicosanoids	COX-2-related signaling ↓; LOX-related signaling ↓	Inflammatory eicosanoid tone ↓	P/R	Inflammation and microenvironment restraint	Mechanistically plausible and historically supported, but generally more secondary than NF-κB/Akt/β-catenin in oncology framing.
10	Clinical Translation Constraint	Bioavailability ↓; exposure consistency ↓	Systemic delivery limitations ↑	—	Formulation-limited translation	Poor solubility, hydrolysis, and variable absorption limit confidence that common oral dosing reproduces stronger in vitro anticancer concentrations.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr

Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱

Source:

Type:

Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.

Scientific Papers found: Click to Expand⟱

5771-

CAPE,

PBG,

Caffeic acid phenethyl ester: Unveiling its potential as a potent apoptosis inducer for combating hypopharyngeal squamous cell carcinoma

in-vitro,

HNSCC,

MMP↓, Casp3↑, survivin↓, XIAP↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Mitochondria & Bioenergetics ⓘ

MMP↓, 1, XIAP↓, 1,

Cell Death ⓘ

Casp3↑, 1, survivin↓, 1,
Total Targets: 4

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells